Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials-Reference-Cited by-同舟云学术

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Published:2015-06 Issue:6 Volume:16 Page:630-637
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Chang Joe Y,Senan Suresh,Paul Marinus A,Mehran Reza J,Louie Alexander V,Balter Peter,Groen Harry J M,McRae Stephen E,Widder Joachim,Feng Lei,van den Borne Ben E E M,Munsell Mark F,Hurkmans Coen,Berry Donald A,van Werkhoven Erik,Kresl John J,Dingemans Anne-Marie,Dawood Omar,Haasbeek Cornelis J A,Carpenter Larry S,De Jaeger Katrien,Komaki Ritsuko,Slotman Ben J,Smit Egbert F,Roth Jack A

Funder

Netherlands Organisation for Health Research and Development

NCI Cancer Center Support (Core)

NCI Clinical and Translational Science Award

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study;Onishi;Cancer,2004

2. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer;Lagerwaard;Int J Radiat Oncol Biol Phys,2008

3. Stereotactic body radiation therapy for inoperable early stage lung cancer;Timmerman;JAMA,2010